Gene · 8291
DYSF: dysferlin
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DYSF: dysferlin. Genes, record 8291. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8291
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O75923 | Dysferlin | 2,080 | 11 | Ensembl, GeneID, HGNC |
Source UniProt
Patents49
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2025169942 A | 2025-11-14 | 949 | O75923 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1276 | O75923 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 69 | O75923 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1343 | O75923 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1343 | O75923 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1276 | O75923 | Espacenet |
| US 12281145 B2 | 2025-04-22 | 11 | O75923 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 27581 | O75923 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 69 | O75923 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 27581 | O75923 | Espacenet |
1 to 10 of 49
See all 49 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants899
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DYSF papers | Newest fiscal year |
|---|---|---|---|
| R01NS047726 | Mechanisms of resealing and rebuilding in muscle repair | 16 | 2025 |
| T32HL007381 | Cardiovascular Sciences Training Grant | 4 | 2025 |
| ZIAAR041203 | Muscle Disease Unit | 4 | 2025 |
| ZIANS003129 | Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies | 4 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 3 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 3 | 2025 |
| P50HD105328 | District of Columbia Intellectual and Developmental Disabilities Research Center (DC-IDDRC) | 3 | 2025 |
| P50NS053672 | Muscular Dystrophy Specialized Research Center | 3 | 2025 |
1 to 10 of 899Source NIH's project files
See all 899 nih grantsPapers2,035
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic Sequencing in Saudi Patients with Systemic Lupus Erythematosus. | Open Access Rheumatol | 2026 | 42770033 | PubTator, text mining | PubMed |
| Case Report: Pediatric immune-mediated necrotizing myopathies mimicking inherited muscle disorders: clinical, paraclinical, and genetic insights from two cases. | Front Pediatr | 2026 | 42729513 | PubTator, text mining | PubMed |
| Integrated Transcriptomic and Machine-Learning Analyses Identify Shared Na+ Overload-Related Gene Signatures in Inflammatory Bowel Disease and Ankylosing Spondylitis. | Genes (Basel) | 2026 | 42650131 | PubTator, text mining | PubMed |
| Genome-wide association study of image-based emphysema scoring in the Swedish CArdioPulmonary bioImage Study (SCAPIS) suggests two new risk loci in smokers. | Respir Res | 2026 | 42634071 | PubTator, text mining | PubMed |
| Novel gain-of-function mutation in dysferlin causes vesicle trafficking defect and IL-1 mediated autoinflammation. | medRxiv | 2026 | 42620509 | PubTator, text mining | PubMed |
| When to think of genetic causes for rhabdomyolysis? A Brazilian single-center exploratory study. | Arq Neuropsiquiatr | 2026 | 42595308 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing in Undiagnosed Muscular Dystrophies: A High Diagnostic Yield and Novel Insights From Iranian Families. | Hum Mutat | 2026 | 42553504 | PubTator, text mining | PubMed |
| Membrane proteomic profiling to identify candidate therapy targets for glioblastoma infiltration. | Neurooncol Adv | 2026 | 42534387 | PubTator, text mining | PubMed |
| Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene. | J Neurol | 2026 | 42474733 | PubTator, text mining | PubMed |
| Vav2 is a master regulator of repair against bacterial pore-forming toxins. | Life Sci Alliance | 2026 | 42425763 | PubTator, text mining | PubMed |
1 to 10 of 2,035
See all 2,035 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8291
GET https://conductscience.org/api/genes/v1/8291/patents?page=2